Our latest news
Craig Jones appointed as our new CEO
We are pleased to announce the appointment of Craig Jones as new Chief Executive Officer of the Royal Osteoporosis Society (ROS).
Professor Neil Gittoes appointed as our new Chair of Trustees
Professor Neil Gittoes, Consultant Endocrinologist and Metabolic Bone Physician at the Queen Elizabeth Hospital Birmingham, Royal Orthopaedic Hospital and Birmingham Children’s Hospital, has been appointed as our new Chair of the Board of Trustees.
New osteoporosis medication approved for use in the UK
We are pleased that a new osteoporosis medication called romosozumab, used to treat post-menopausal women at high risk of breaking a bone, has been approved by the European Medicines Agency (EMA).
Our experts respond to new study about continuing breast cancer risks after HRT
A study has found the risk of breast cancer when using hormone replacement therapy (HRT) is higher than previously thought and continues when HRT is stopped, prompting new information from the MHRA. However, our experts say that HRT still has an important role to play in osteoporosis care.
Our thoughts on the new biosimilars for osteoporosis available on the NHS
Two new biosimilars have been launched for the osteoporosis medication teriparatide. This is positive news that we hope will improve access to the treatment across the UK.